DK3172209T3 - Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid - Google Patents

Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid Download PDF

Info

Publication number
DK3172209T3
DK3172209T3 DK15744702.0T DK15744702T DK3172209T3 DK 3172209 T3 DK3172209 T3 DK 3172209T3 DK 15744702 T DK15744702 T DK 15744702T DK 3172209 T3 DK3172209 T3 DK 3172209T3
Authority
DK
Denmark
Prior art keywords
triazin
quinolin
imidazo
benzamide
ylmethyl
Prior art date
Application number
DK15744702.0T
Other languages
Danish (da)
English (en)
Inventor
Elisabete Goncalves
Christin Tauchmann
Shau-Fong Yen
Sudha Vippagunta
Zhixin Zong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3172209(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3172209T3 publication Critical patent/DK3172209T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK15744702.0T 2014-07-25 2015-07-22 Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid DK3172209T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Publications (1)

Publication Number Publication Date
DK3172209T3 true DK3172209T3 (da) 2021-02-22

Family

ID=53762251

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15744702.0T DK3172209T3 (da) 2014-07-25 2015-07-22 Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid

Country Status (31)

Country Link
US (5) US10085993B2 (enExample)
EP (2) EP3848376A1 (enExample)
JP (3) JP6770946B2 (enExample)
KR (2) KR20230136693A (enExample)
CN (2) CN115364061A (enExample)
AR (1) AR101286A1 (enExample)
AU (4) AU2015293539A1 (enExample)
CA (1) CA2954840A1 (enExample)
CL (1) CL2017000180A1 (enExample)
CO (1) CO2017000586A2 (enExample)
DK (1) DK3172209T3 (enExample)
EA (2) EA039220B1 (enExample)
EC (1) ECSP17011672A (enExample)
ES (1) ES2857523T3 (enExample)
FR (1) FR22C1058I2 (enExample)
GT (1) GT201700007A (enExample)
HU (2) HUE053346T2 (enExample)
IL (1) IL250166B (enExample)
JO (1) JO3618B1 (enExample)
MX (2) MX379279B (enExample)
MY (1) MY187276A (enExample)
NL (1) NL301208I2 (enExample)
NO (1) NO2022058I1 (enExample)
PE (1) PE20170523A1 (enExample)
PH (1) PH12017500121A1 (enExample)
PL (1) PL3172209T3 (enExample)
PT (1) PT3172209T (enExample)
SG (2) SG11201700147SA (enExample)
SI (1) SI3172209T1 (enExample)
TW (2) TW202200148A (enExample)
WO (1) WO2016012963A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid
TWI736660B (zh) 2016-08-10 2021-08-21 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
US11407735B2 (en) 2019-05-16 2022-08-09 Novartis Ag Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
JP7675071B2 (ja) * 2019-10-24 2025-05-12 ハンミ ファーマシューティカル カンパニー リミテッド がん細胞の成長を阻害するアミド誘導体を含む医薬調製物およびそれを含有する医薬品
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762A (zh) * 2021-02-03 2022-08-05 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2023324893A1 (en) * 2022-08-19 2025-03-13 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
PL2497470T3 (pl) 2006-11-22 2016-04-29 Incyte Holdings Corp Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy
JP6022158B2 (ja) 2008-05-21 2016-11-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法
PT4066821T (pt) * 2009-11-09 2025-06-03 Wyeth Llc Formulações de comprimidos de maleato de neratinib
JP5846647B2 (ja) 2010-02-25 2016-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン製剤
NZ603686A (en) * 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
WO2012006298A2 (en) 2010-07-06 2012-01-12 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
RU2705095C2 (ru) 2012-08-16 2019-11-05 Новартис Аг Комбинация ингибитора pik3 и ингибитора с-мет
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid

Also Published As

Publication number Publication date
MY187276A (en) 2021-09-17
US10596178B2 (en) 2020-03-24
FR22C1058I1 (fr) 2023-01-06
CL2017000180A1 (es) 2017-09-15
KR20170039211A (ko) 2017-04-10
EA201790259A1 (ru) 2017-06-30
ECSP17011672A (es) 2018-03-31
SG11201700147SA (en) 2017-02-27
AU2021202500A1 (en) 2021-05-20
US20210113569A1 (en) 2021-04-22
IL250166A0 (en) 2017-03-30
CA2954840A1 (en) 2016-01-28
EA039220B1 (ru) 2021-12-20
EA202191301A1 (ru) 2021-11-30
BR112017000953A2 (pt) 2017-11-14
US20190015418A1 (en) 2019-01-17
SG10201900648SA (en) 2019-02-27
AU2018207947A1 (en) 2018-08-09
NL301208I2 (nl) 2025-03-20
JP2017521469A (ja) 2017-08-03
SI3172209T1 (sl) 2021-03-31
CO2017000586A2 (es) 2017-06-20
KR102581121B1 (ko) 2023-09-21
CN115364061A (zh) 2022-11-22
PH12017500121A1 (en) 2017-05-29
AR101286A1 (es) 2016-12-07
NZ728089A (en) 2024-01-26
AU2015293539A1 (en) 2017-02-02
MX2017001177A (es) 2017-05-01
JP2020114852A (ja) 2020-07-30
US20250339440A1 (en) 2025-11-06
AU2020200912B2 (en) 2021-01-28
CN106714784A (zh) 2017-05-24
JP7002587B2 (ja) 2022-01-20
MX2021000595A (es) 2021-04-13
HUS2200054I1 (hu) 2023-01-28
ES2857523T3 (es) 2021-09-29
US20220249498A1 (en) 2022-08-11
WO2016012963A1 (en) 2016-01-28
HUE053346T2 (hu) 2021-06-28
JP6770946B2 (ja) 2020-10-21
PL3172209T3 (pl) 2021-06-14
TW202200148A (zh) 2022-01-01
JP2022046659A (ja) 2022-03-23
JO3618B1 (ar) 2020-08-27
TWI724993B (zh) 2021-04-21
MX379279B (es) 2025-03-11
US10085993B2 (en) 2018-10-02
EP3172209B1 (en) 2020-12-02
KR20230136693A (ko) 2023-09-26
IL250166B (en) 2021-01-31
EP3848376A1 (en) 2021-07-14
GT201700007A (es) 2018-12-18
US12208101B2 (en) 2025-01-28
FR22C1058I2 (fr) 2023-11-17
TW201613595A (en) 2016-04-16
AU2020200912A1 (en) 2020-02-27
PE20170523A1 (es) 2017-05-17
US20170231997A1 (en) 2017-08-17
EP3172209A1 (en) 2017-05-31
PT3172209T (pt) 2021-02-11
NO2022058I1 (no) 2022-12-16

Similar Documents

Publication Publication Date Title
FR22C1058I1 (fr) Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
IL259169A (en) Novel pyrazolo pyrimidine derivatives
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
DK3305785T3 (da) Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf
ZA201600079B (en) Active mixtures
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
PL3359543T3 (pl) Pochodne kukurbiturylu
IL254168A0 (en) Use of 3,2-dihydroimidazo[2,1-c]converted quinazolines
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
SI3114126T1 (sl) Derivati 1,2-dihidro-3H-pirolo(1,2-C)imidazol-3-ona in njihova uporaba kot antibakterijska sredstva
LT3064498T (lt) Pirazolpirimidono arba piroltriazono dariniai, jų paruošimo būdas ir jų farmacinis panaudojimas
PT3149005T (pt) Derivados de amida de compostos de 1-oxa-4,9-diazaespiro undecano tendo atividade multimodal contra a dor
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
IL253779A0 (en) Compounds with antitumor activity
GB201802644D0 (en) Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
HRP20180788T1 (hr) [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti
IL274868A (en) History of imidazopyridine and their use as medicine
IL248490A0 (en) History of cyclics and pharmaceutical preparations that include them
GB201416851D0 (en) Active Retroreflector
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่
TH1601003084A (th) สิ่งจัดเตรียมใช้ภายนอกที่ผิวหนัง
GB201602819D0 (en) Humanii beacon unit
TH1501005812A (th) อนุพันธ์แนพธิริดีนที่ใช้ประโยชน์เป็นแอลฟา-v-บีตา-6 อินทีกรินแอนทาโกนิสต์